Record ID: MS-N091
Family: Nutrition, foods and nutraceuticals
Clinical question: Do lycopene supplements or tomato products control localized or recurrent prostate cancer?
Evidence label: Small randomized and single-arm studies; clinical benefit unproven
Evidence at a glance
Benefit: Some small pre-prostatectomy studies reported biomarker or pathology differences; biochemical-relapse studies did not show a dependable PSA response.
Certainty: Very low for cancer control because studies were small, short, heterogeneous and often used surrogate outcomes.
Risk: Generally well tolerated in studied doses; concentrated products can cause gastrointestinal symptoms and are not equivalent to tomatoes in a usual diet.
Cancer control: No reliable evidence establishes reduced recurrence, metastasis or mortality.
What was studied
A pilot randomized study assigned 26 men with localized prostate cancer to tomato oleoresin providing lycopene 15 mg twice daily or no supplement for three weeks before prostatectomy. Another presurgical trial allocated 45 men to 15, 30 or 45 mg/day or control for about 30 days.
These “window” studies mainly assessed prostate tissue, PSA, hormones and proliferation markers. Separate phase I–II studies in biochemical relapse tested longer supplementation against PSA responses.
What the results mean
The 26-person trial reported more organ-confined disease and smaller tumor volume in the supplement group, but the trial was tiny, short and did not use a blinded placebo. The dose-ranging trial found changes in plasma lycopene and selected biomarkers, not a patient-centered cancer outcome.
In a biochemical-relapse phase I–II study, the tested lycopene doses produced no discernible PSA response. A North Central Cancer Treatment Group phase II study in androgen-independent disease reported a confirmed PSA response in 1 patient (2%).
Limits and uncertainty
Pathology differences after only a few weeks are vulnerable to chance and baseline imbalance. PSA and Ki-67 are not substitutes for recurrence-free or overall survival.
Tomato foods, oleoresin capsules and synthetic lycopene have different matrices and doses. Positive early studies and negative later studies should be considered together.
Safety and practical context
Research doses are not personal prescriptions. Discuss supplements around surgery and treatment; product purity and co-ingredients vary.
Eating tomato foods is a dietary choice, not an evidence-based treatment for prostate cancer. Standard surveillance and treatment decisions should not be delayed.
Questions for the care team
- Which formulation and dose produced the claimed result?
- Was the endpoint tissue lycopene, PSA, pathology, recurrence or survival?
- Could the short, unblinded design explain the finding?
- Will the product interfere with surgery, medicines or nutrition goals?
Sources
- Pilot pre-prostatectomy randomized study (PMID 11489752)
- Dose-ranging pre-prostatectomy trial (PMID 20354574)
- Biochemical-relapse phase I–II study (PMID 16765186)
- NCI PDQ: prostate cancer, nutrition and dietary supplements
Funding and conflicts
Funding and conflicts varied across the small studies and were not fully verified for this record. Results should not be generalized across commercial lycopene products.
Last literature search: October 21, 2026
Record appraised: October 21, 2026
This educational record is not individualized medical advice. Research doses and schedules are not personal prescriptions; do not delay or replace evidence-based cancer care.
